Friday, March 7th
|
AM
|
|
| 7:00-8:00 |
Breakfast Buffet
|
| 8:00-8:15 |
Welcome and Introduction
Ranjan Duara, MD
|
| 8:15-9:15 |
Keynote Address: "What Determines the Risk of and Rate of Progression in Alzheimer's Disease: Mechanisms and Modifiers"
Denis Evans, MD
|
| 9:15-11:15 |
Mini-Symposium: Pathogenic Mechanisms for Cognitive Impairment in Animals and Humans
Chair: Carl Cotman, PhD
|
| |
Amyloid Metabolism and Cognitive Impairment in Animals and Humans
Todd Golde, PhD
|
| |
Tau Pathology and Cognitive Impairment in Animals and Humans
Karen Duff, PhD
|
| |
Protein Misfolding in the Pathogenesis of AD
JoAnne McLaurin, PhD
|
| |
Inflammation and Brain Aging
Stephen Bondy, PhD
|
| |
Inflammatory Cytokines and Cognitive Impairment in Aging
Philip Wolf, MD
|
| |
Hypertension, Metabolic Syndrome and Cognitive Impairment
Jose Luchsinger, MD, MPH
|
| 11:15-11:30 |
Break
|
| 11:30-12:15 |
Open Discussion
|
| 12:15-1:30 |
Lunch Break
|
PM
|
|
| 1:30-4:00 |
Mini-Symposium: Biomarkers for Measuring Progression and the Effects of Treatment in AD
Chair: Mike Weiner, MD
|
| |
Cognitive Measurement
Robert Wilson, PhD
|
| |
Volumetric MRI (the ADNI Experience)
Clifford Jack, MD
|
| |
4 Tesla MRI in MCI and Early AD
Michael Weiner, MD
|
| |
Amyloid Imaging with [C-11] PIB in Normal Aging, MCI and AD
Colin Masters, MD, PhD
|
| |
Amyloid Imaging with [F-18] 1, 4-diphenyltriazoles
Mike Pontecorvo, PhD
|
| |
PET FDG and Amyloid and Tau Imaging with [F-18] FDDNP in Early AD
Gary Small, MD
|
| |
CSF Biomarkers in MCI and Early AD
John Morris, MD
|
| 4:00-4:15 |
Break
|
| 4:15-5:00 |
Open Discussion
|
| 5:30-7:00 |
Panel Discussion: Disclosing the Diagnosis: Why, When and How
Chair: Mary Ganguli, MD, MPH
Panelists (Ronald Petersen, MD, PhD; Angela Jefferson, PhD; Mary Mittelman, DrPH; Soo Borson, MD; Eric Rodriguez, MD; Orien Reid, MSW)
|
| 7:00-9:00 |
Welcome Dinner
|
Saturday, March 8th
|
AM
|
|
| 7:30-8:30 |
Breakfast Buffet
|
| 8:30-8:45 |
Announcements and Introductions
Ranjan Duara, MD
|
| 8:45-10:30 |
Mini-Symposium: Non-Pharmacological Treatment and Prevention of Early AD and
Other Dementias
Chair: Huntington Potter, PhD
|
| |
Hematopoeitic Growth Factors for Brain Repair
Juan Sanchez-Ramos, MD, PhD
|
| |
Risk Factors for Cognitive Decline
Laura Fratiglioni, MD, PhD
|
| |
Cognitive and Environmental Stimulation for both Treatment and Prevention of Alzheimer's Disease: Transgenic Mouse Studies
Gary Arendash, PhD
|
| |
Cognitive Rehabilitation in MCI and Early AD
David Loewenstein, PhD
|
| |
The Role of Exercise and Intellectual Engagement on AD and Cognition of older adults
Art Kramer, PhD
|
| 10:30-10:45 |
Break
|
| 10:45-11:30 |
Open Discussion
|
| 11:30-1:00 |
Lunch Break
|
PM
|
|
| 1:00-3:00 |
Mini-Symposium: Potential Disease Modifying Agents for Treatment and Prevention of AD
Chair: Paul Aisen, MD
|
| |
Drug Development for AD and Prodromal AD: an Overview
Paul Aisen, MD
|
| |
Clioquinol (Reformulated)
Colin Masters, MD
|
| |
Immunotherapy for AD (Immunoglobulin Infusion)
Norman Relkin, MD, PhD
|
| |
Immunotherapy for AD (Antibody Infusion)
Michael Grundman, MD
|
| |
Flurizan: A Gamma Secretase Modulating Agent
Kenton Zavitz, PhD
|
| |
LY450139: a Gamma secretase inhibitor
Eric Siemers, MD, PhD
|
| 3:00-3:15 |
Break
|
| 3:15-4:00 |
Open Discussion
|
| 4:00 |
Adjourn
|
